IVIG is an option for treatment of patients with NMDA. Diagnosis of NMDA requires expert consultation.
IVIG is used in conjunction with immunosuppressive medications and/or plasmapheresis.
Initial dose: Total dose of 2 g/kg divided over 2 to 5 days in adults and children.
Maintenance dose may be considered depending on response to treatment.